← All trials
NCT01188512
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2010
- Primary completion
- Jun 1, 2011
- Completion date
- Jan 1, 2012
- First posted
- —
- Last posted
- —
- Enrollment
- 48
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- Institut National de la Santé Et de la Recherche Médicale, FranceLead sponsor
- European UnionCollaborator
- InnogeneticsCollaborator
- Institut National de la Santé Et de la Recherche Médicale, FranceStudy director
- Swedish Institute for Infectious Disease ControlOverall official - principal investigator
- Swedish Institute for Infectious Disease ControlCollaborator
- Karolinska InstituteOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.